

Medicines Access and Use in Asia: Opportunities & Challenges in Light of Economic Growth


Anita Wagner

Department of Population Medicine


Harvard Medical School & Harvard Pilgrim Health Care Institute

Yong Loo Lin School of Medicine


National University of Singapore




Health & Wealth Increased




Chronic Conditions are Leading Causes of Death in Most of the World




Rapid Increase in Global Medicines Spending



Coverage Expansion




Thailand



Asian Countries, 2005-7


Three Dimensions of Coverage Expansion



Competing Pharmaceutical Policy Objectives


Keeping Costs Affordable

To patient and to the health system



Improving Equitable Access

Available to the poor



Encouraging Appropriate Use

Necessary, safe, effective, properly taken




Risk Protection Scheme Levers

- **Defined populations**
 - **Members & dependents**
 - **Providers**
- **Information**
 - **Member needs**
 - **Provider characteristics**
 - **Services provided**
 - **Reimbursements claimed**
 - **Expenditures**
- **Policy tools**
 - **Cost**
 - **Quality**
 - **Cost + Quality = Value**



Risk Protection Increases Access and Decreases Burden



Critical Need for Outpatient Medicines Coverage



BMC Health Services Research

Open Access

Research article

Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines

Anita K Wagner^{*†1}, Madeleine Valera^{†2}, Amy J Graves^{†1}, Sheila Laviña^{†3} and Dennis Ross-Degnan^{†1}

Few LMIC Schemes Use Available Pharmaceutical Policy Options



Contents lists available at ScienceDirect

Health Policy

journal homepage: www.elsevier.com/locate/healthpol



Review

Active pharmaceutical management strategies of health insurance systems to improve cost-effective use of medicines in low- and middle-income countries: A systematic review of current evidence

Summary

- Asian countries face shifts in disease burden, rising demands, inequitable access
- Risk protection schemes have levers to balance medicines access, affordability, and appropriate use
- To be efficient and sustainable, systems need to
 - Implement medicines coverage policies
 - Monitor & evaluate impacts of policy decisions
- Systems could benefit from shared experiences



Contact information

awagner@hms.harvard.edu